Excess Heparin Dosing Among Fibrinolytic-treated Patients with ST-Segment Elevation Myocardial Infarction

American Journal of Medicine

Volumn 121, Issue 9, 2008, Pages 805-810

  Wang, Tracy Y ^a   Chen, Anita Y ^a   Alexander, Karen P ^a   Ohman, E Magnus ^a   Gibler, W Brian ^b   Peterson, Eric D ^a   Roe, Matthew T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Bleeding; Fibrinolysis; Patient care

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BODY WEIGHT; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GENDER; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; ST SEGMENT ELEVATION HEART INFARCTION; TREATMENT OUTCOME;

AGED; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 50049128434     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.04.023     Document Type: Article

References (18)

1. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 329 (1993) 1615-1622
2. Mahaffey K.W., Granger C.B., Collins R., et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 77 (1996) 551-556
3. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 44 (2004) E1-E211
4. Van de Werf F., Ardissino D., Betriu A., et al., Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 24 (2003) 28-66
5. Zeger S.L., and Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42 (1986) 121-130
6. Moscucci M., Fox K.A., Cannon C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1815-1823
7. Cannon C.P. Thrombolysis medication errors: benefits of bolus thrombolytic agents. Am J Cardiol 85 (2000) 17C-22C
8. Granger C.B., Hirsch J., Califf R.M., et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 93 (1996) 870-878
9. Giugliano R.P., McCabe C.H., Antman E.M., et al., Thrombolysis in Myocardial Infarction (TIMI) Investigators. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 141 (2001) 742-750
10. Alexander K.P., Chen A.Y., Roe M.T., et al., CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
11. Freedman J.E., Becker R.C., Adams J.E., et al., American Heart Association. Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. Medication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. Circulation 106 (2002) 2623-2629
12. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation 90 (1994) 1631-1637
13. Antman E.M. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 94 (1996) 911-921
14. Hochman J.S., Wali A.U., Gavrila D., et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 138 2 Pt 1 (1999) 313-318
15. Sabatine M.S., Cannon C.P., Gibson C.M., et al., CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
16. Chen Z.M., Jiang L.X., Chen Y.P., et al., COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
17. Antman E.M., Morrow D.A., McCabe C.H., et al., ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
18. Yusuf S., Mehta S.R., Chrolavicius S., et al., OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295 (2006) 1519-1530